These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

167 related articles for article (PubMed ID: 16862527)

  • 1. Composition, quality control, and labeling of plasma-derived products for the treatment of von Willebrand disease.
    Mazurier C
    Semin Thromb Hemost; 2006 Jul; 32(5):529-36. PubMed ID: 16862527
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Von Willebrand factor/factor VIII concentrates in the treatment of von Willebrand disease.
    Batlle J; López-Fernández MF; Fraga EL; Trillo AR; Pérez-Rodríguez MA
    Blood Coagul Fibrinolysis; 2009 Mar; 20(2):89-100. PubMed ID: 19786936
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The factor VIII/von Willebrand factor complex: basic and clinical issues.
    Federici AB
    Haematologica; 2003 Jun; 88(6):EREP02. PubMed ID: 12826528
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparative analysis and classification of von Willebrand factor/factor VIII concentrates: impact on treatment of patients with von Willebrand disease.
    Budde U; Metzner HJ; Müller HG
    Semin Thromb Hemost; 2006 Sep; 32(6):626-35. PubMed ID: 16977573
    [TBL] [Abstract][Full Text] [Related]  

  • 5. PFA-100 monitoring of von Willebrand factor (VWF) responses to desmopressin (DDAVP) and factor VIII/VWF concentrate substitution in von Willebrand disease type 1 and 2.
    van Vliet HH; Kappers-Klunne MC; Leebeek FW; Michiels JJ
    Thromb Haemost; 2008 Sep; 100(3):462-8. PubMed ID: 18766263
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparison of the pharmacokinetics of two von Willebrand factor concentrates [Biostate and AHF (High Purity)] in people with von Willebrand disorder. A randomised cross-over, multi-centre study.
    Favaloro EJ; Lloyd J; Rowell J; Baker R; Rickard K; Kershaw G; Street A; Scarff K; Barrese G; Maher D; McLachlan AJ
    Thromb Haemost; 2007 Jun; 97(6):922-30. PubMed ID: 17549293
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Intravenous DDAVP and factor VIII-von Willebrand factor concentrate for the treatment and prophylaxis of bleedings in patients With von Willebrand disease type 1, 2 and 3.
    Michiels JJ; van Vliet HH; Berneman Z; Gadisseur A; van der Planken M; Schroyens W; van der Velden A; Budde U
    Clin Appl Thromb Hemost; 2007 Jan; 13(1):14-34. PubMed ID: 17164493
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Guidelines for the evaluation of intravenous desmopressin and von Willebrand factor/factor VIII concentrate in the treatment and prophylaxis of bleedings in von Willebrand disease types 1, 2, and 3.
    Michiels JJ; Gadisseur A; van der Planken M; Schroyens W; van de Velden A; Berneman Z
    Semin Thromb Hemost; 2006 Sep; 32(6):636-45. PubMed ID: 16977574
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A systematic overview of the first pasteurised VWF/FVIII medicinal product, Haemate P/ Humate -P: history and clinical performance.
    Berntorp E; Archey W; Auerswald G; Federici AB; Franchini M; Knaub S; Kreuz W; Lethagen S; Mannucci PM; Pollmann H; Scharrer I; Hoots K
    Eur J Haematol Suppl; 2008 May; (70):3-35. PubMed ID: 18380871
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficacy and safety of a high purity, double virus inactivated factor VIII/von Willebrand factor concentrate (Biostate) in patients with von Willebrand disorder requiring invasive or surgical procedures.
    Shortt J; Dunkley S; Rickard K; Baker R; Street A
    Haemophilia; 2007 Mar; 13(2):144-8. PubMed ID: 17286766
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Managing patients with von Willebrand disease type 1, 2 and 3 with desmopressin and von Willebrand factor-factor VIII concentrate in surgical settings.
    Michiels JJ; van Vliet HH; Berneman Z; Schroyens W; Gadisseur A
    Acta Haematol; 2009; 121(2-3):167-76. PubMed ID: 19506363
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Management of inherited von Willebrand disease in 2006.
    Federici AB
    Semin Thromb Hemost; 2006 Sep; 32(6):616-20. PubMed ID: 16977571
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The von Willebrand disease prophylaxis network (vWD PN): exploring a treatment concept.
    Berntorp E; Abshire T;
    Thromb Res; 2006; 118 Suppl 1():S19-22. PubMed ID: 16545435
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Time to think outside the box? Proposals for a new approach to future pharmacokinetic studies of von Willebrand factor concentrates in people with von Willebrand disease.
    Favaloro EJ; Kershaw G; McLachlan AJ; Lloyd J
    Semin Thromb Hemost; 2007 Nov; 33(8):745-58. PubMed ID: 18175280
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Highly purified VWF/FVIII concentrates in the treatment and prophylaxis of von Willebrand disease: the PRO. WILL Study.
    Federici AB
    Haemophilia; 2007 Dec; 13 Suppl 5():15-24. PubMed ID: 18078393
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Plasma-derived biological medicines used to promote haemostasis.
    Ofosu FA; Freedman J; Semple JW
    Thromb Haemost; 2008 May; 99(5):851-62. PubMed ID: 18449414
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Restoration of plasma von Willebrand factor deficiency is sufficient to correct thrombus formation after gene therapy for severe von Willebrand disease.
    De Meyer SF; Vandeputte N; Pareyn I; Petrus I; Lenting PJ; Chuah MK; VandenDriessche T; Deckmyn H; Vanhoorelbeke K
    Arterioscler Thromb Vasc Biol; 2008 Sep; 28(9):1621-6. PubMed ID: 18556568
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Recessive von Willebrand disease type 2 Normandy: variable expression of mild hemophilia and VWD type 1.
    Michiels JJ; Gadisseur A; Vangenegten I; Schroyens W; Berneman Z
    Acta Haematol; 2009; 121(2-3):119-27. PubMed ID: 19506358
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prophylaxis in von Willebrand disease.
    Berntorp E
    Haemophilia; 2008 Nov; 14 Suppl 5():47-53. PubMed ID: 18786010
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinical efficacy in bleeding and surgery in von Willebrand patients treated with Fanhdi a highly purified, doubly inactivated FVIII/VWF concentrate.
    Hernandez-Navarro F; Quintana M; Jimenez-Yuste V; Alvarez MT; Fernandez-Morata R
    Haemophilia; 2008 Sep; 14(5):963-7. PubMed ID: 18624696
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.